[144] Ionis Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Ionis Pharmaceuticals (IONS) submitted a Form 144 notifying the proposed sale of 45,000 shares of common stock through Stifel Nicolaus & Company, with an aggregate market value of $2,658,996.00. The filing lists 159,391,229 shares outstanding and names Nasdaq as the exchange with an approximate sale date of 09/03/2025.

The securities were acquired by the seller on 01/31/2022 via an option exercise for 60,000 shares. The planned method of payment on sale is cash. The filing reports no securities sold by the person in the past three months and contains the standard attestation about absence of undisclosed material adverse information.

Insights

Securities Analyst

TL;DR: Routine insider sale notice: 45,000 shares (~$2.66M) planned to be sold on 09/03/2025; acquired by option exercise in 2022.

This Form 144 is a procedural disclosure required when an affiliate proposes an off-exchange sale that exceeds the Rule 144 thresholds. Key facts: the insider acquired 60,000 shares via option exercise on 01/31/2022 and now proposes to sell 45,000 shares through Stifel Nicolaus with an aggregate stated market value of $2,658,996. The filing indicates no sales in the prior three months, and identifies Nasdaq as the exchange. As presented, the notice contains no performance metrics, company financials, or additional context about intent or trading plans.

Corporate Governance Expert

TL;DR: Compliance-level disclosure only; the filing documents an insider's planned sale but provides no material governance concerns.

The document fulfills the Rule 144 notice requirement by disclosing the amount, acquisition date and nature (option exercise) of the securities, broker information, and the intended sale date. It includes the customary representation that the seller is not aware of undisclosed material adverse information. There are no statements of trading-plan adoption dates or indications of Rule 10b5-1 reliance in the visible fields.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Stifel Nicolaus & Company Inc 501 N Broadway St. Louis MO 63102	45000	2658996.00	159391229	09/03/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/31/2022	Option Exercise	Issuer			60000	09/03/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Ionis Pharmaceuticals' Form 144 (IONS) disclose?

The filing discloses a proposed sale of 45,000 shares of common stock with an aggregate market value of $2,658,996.00, to be sold via Stifel Nicolaus on or about 09/03/2025.

How and when were the shares being sold in the IONS Form 144 acquired?

The shares were acquired on 01/31/2022 through an option exercise, with 60,000 shares shown as acquired at that time.

Does the Form 144 show any securities sold in the past three months for IONS?

No. The filing states "Nothing to Report" for securities sold during the past three months by the person for whose account the securities are to be sold.

Which broker and exchange are listed in the Ionis Form 144?

The broker listed is Stifel Nicolaus & Company Inc (501 N Broadway St. Louis MO 63102) and the exchange named is Nasdaq.

Does the filing indicate payment type or trading-plan reliance?

The planned payment on sale is listed as cash. The filing includes the standard attestation about undisclosed material information and shows no explicit date for any Rule 10b5-1 plan adoption in the provided fields.